# Biotech Growth Portfolio

*Catalyst-driven biotech selection focusing on pipeline value and upcoming catalysts*

## Investment Thesis

This Biotech Growth portfolio contains 17 positions with 0 high-conviction holdings.
Average composite score is 63/100.

Strategy: Catalyst-driven biotech selection focusing on pipeline value and upcoming catalysts

Position sizing uses conviction-based weighting to optimize exposure.

## Portfolio Summary

**Total Value:** $100,000
**Invested:** $90,000 (90.0%)
**Cash Buffer:** $10,000 (10.0%)
**Holdings:** 17 stocks across 1 sectors

### Complete Holdings List

| # | Ticker | Name | Weight | Conviction | Score | Market Cap | Rationale |
|---|--------|------|--------|------------|-------|------------|-----------|
| 1 | **CTMX** | CTMX | 5.5% | MEDIUM | 64 | $913M | Good setup with moderate catalyst visibi |
| 2 | **ERAS** | ERAS | 5.5% | MEDIUM | 64 | $2.7B | Good setup with moderate catalyst visibi |
| 3 | **NRIX** | NRIX | 5.4% | MEDIUM | 64 | $1.9B | Good setup with moderate catalyst visibi |
| 4 | **STOK** | STOK | 5.4% | MEDIUM | 64 | $1.6B | Good setup with moderate catalyst visibi |
| 5 | **DAWN** | DAWN | 5.4% | MEDIUM | 63 | $1.0B | Good setup with moderate catalyst visibi |
| 6 | **ABEO** | ABEO | 5.4% | MEDIUM | 63 | $285M | Good setup with moderate catalyst visibi |
| 7 | **TWST** | TWST | 5.3% | MEDIUM | 62 | $2.5B | Good setup with moderate catalyst visibi |
| 8 | **VRDN** | VRDN | 5.3% | MEDIUM | 62 | $3.2B | Good setup with moderate catalyst visibi |
| 9 | **AMLX** | AMLX | 5.2% | MEDIUM | 62 | $1.6B | Good setup with moderate catalyst visibi |
| 10 | **GPCR** | GPCR | 5.2% | MEDIUM | 62 | $6.3B | Good setup with moderate catalyst visibi |
| 11 | **WVE** | WVE | 5.2% | MEDIUM | 62 | $2.5B | Good setup with moderate catalyst visibi |
| 12 | **CERT** | CERT | 5.2% | MEDIUM | 62 | $1.5B | Good setup with moderate catalyst visibi |
| 13 | **MDXG** | MDXG | 5.2% | MEDIUM | 62 | $803M | Good setup with moderate catalyst visibi |
| 14 | **TERN** | TERN | 5.2% | MEDIUM | 61 | $4.0B | Good setup with moderate catalyst visibi |
| 15 | **TRVI** | TRVI | 5.2% | MEDIUM | 61 | $1.3B | Good setup with moderate catalyst visibi |
| 16 | **TNGX** | TNGX | 5.2% | MEDIUM | 61 | $1.8B | Good setup with moderate catalyst visibi |
| 17 | **LXRX** | LXRX | 5.2% | MEDIUM | 61 | $498M | Good setup with moderate catalyst visibi |

### Sector Allocation

| Sector | Weight | Stocks |
|--------|--------|--------|
| Healthcare | 90.0% | 17 |

### Risk Metrics

- **Holdings:** 17
- **Sectors:** 1
- **Max Position:** 5.5%
- **Max Sector:** 90.0%
- **Avg Score:** 62.5
- **BUY Signal Coverage:** 0%
- **Avg PE:** 44.4
- **Portfolio Yield:** 0.00%

### Top Holdings - Detailed Analysis

#### CTMX - CTMX

**Weight:** 5.5% | **Conviction:** MEDIUM | **Score:** 64

**Score Breakdown:**
- pipeline_value: 15.2
- catalyst_score: 15.0
- cash_runway: 11.2
- fundamental_strength: 6.0
- revenue_growth: 5.5

**Bull Case:**
- ✓ Bullish options flow - smart money buying

**Bear Case / Risks:**
- ✗ Small cap ($913M) - higher volatility

**Key Catalysts:**
- → Institutional accumulation
- → Clinical data readout
- → Partnership/M&A potential

---

#### ERAS - ERAS

**Weight:** 5.5% | **Conviction:** MEDIUM | **Score:** 64

**Score Breakdown:**
- catalyst_score: 15.0
- pipeline_value: 13.7
- cash_runway: 11.2
- revenue_growth: 7.0
- institutional_flow: 5.0

**Bull Case:**
- ✓ Mid cap ($2.7B) with growth potential
- ✓ Very positive news sentiment
- ✓ Bullish options flow - smart money buying

**Bear Case / Risks:**
- ✗ Negative ROE (-32.0%)

**Key Catalysts:**
- → Positive news flow continuation
- → Institutional accumulation
- → Clinical data readout

---

#### NRIX - NRIX

**Weight:** 5.4% | **Conviction:** MEDIUM | **Score:** 64

**Score Breakdown:**
- catalyst_score: 15.0
- pipeline_value: 13.6
- cash_runway: 11.2
- revenue_growth: 7.0
- institutional_flow: 5.0

**Bull Case:**
- ✓ Mid cap ($1.9B) with growth potential
- ✓ Very positive news sentiment
- ✓ Bullish options flow - smart money buying

**Bear Case / Risks:**
- ✗ Negative ROE (-65.3%)

**Key Catalysts:**
- → Positive news flow continuation
- → Institutional accumulation
- → Clinical data readout

---

#### STOK - STOK

**Weight:** 5.4% | **Conviction:** MEDIUM | **Score:** 64

**Score Breakdown:**
- catalyst_score: 15.0
- pipeline_value: 11.7
- cash_runway: 11.2
- revenue_growth: 9.0
- fundamental_strength: 6.0

**Bull Case:**
- ✓ Mid cap ($1.6B) with growth potential
- ✓ Bullish options flow - smart money buying

**Bear Case / Risks:**
- ✗ General market risk

**Key Catalysts:**
- → Institutional accumulation
- → Clinical data readout
- → Partnership/M&A potential

---

#### DAWN - DAWN

**Weight:** 5.4% | **Conviction:** MEDIUM | **Score:** 63

**Score Breakdown:**
- catalyst_score: 15.0
- pipeline_value: 14.2
- cash_runway: 11.2
- revenue_growth: 5.5
- institutional_flow: 5.0

**Bull Case:**
- ✓ Mid cap ($1.0B) with growth potential
- ✓ Very positive news sentiment
- ✓ Bullish options flow - smart money buying

**Bear Case / Risks:**
- ✗ Negative ROE (-30.2%)

**Key Catalysts:**
- → Positive news flow continuation
- → Institutional accumulation
- → Clinical data readout

---

### Key Portfolio Risks

- Sector concentration: Healthcare at 90%
- Binary clinical/regulatory risk
- Dilution risk for cash-burning companies
- General market/systematic risk

### Rebalance Triggers

- Monthly review of position weights
- Position exceeds max weight by >2%
- Sector exceeds limit by >5%
- Major catalyst event (FDA, data readout)
- Cash runway drops below 12 months
